Sipuleucel-T: Autologous cellular immunotherapy for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer

Pas encore traduit Pas encore traduit
Auteurs
Catégorie Primary study
JournalJournal of Cancer
Year 2011
Sipuleucel T is an autologous cellular immunotherapy designed to stimulate an immune response in men diagnosed with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Sipuleucel T improves overall survival and provides an additional treatment option for this patient population. © Ivyspring International Publisher.
Epistemonikos ID: cd5944dadbbe79d6e5abac8f64db11b1b49e4257
First added on: Feb 04, 2025